Articles Tagged With: MIS-C
-
Double Trouble: Vaccines Lag, Virulent Mpox Clade 1 Spreads
The Centers for Disease Control and Prevention has released two health advisory alerts only a week apart, one dealing with the “urgent need” to vaccinate people for seasonal respiratory viruses; the second warning that a virulent type of mpox (monkeypox) virus is spreading in Africa.
-
Uncommon Diagnoses that Cannot Be Missed: An Update
There are a variety of uncommon pediatric conditions that, if not detected, may result in devastating consequences. The authors review and update the current standard of care for a variety of conditions, including necrotizing fasciitis, DRESS syndrome, Kawasaki disease, MIS-C, Lemierre's, and RPA.
-
Researchers Use Advanced Technology to Detect MIS-C
Scientists want to improve diagnostic techniques for multisystem inflammatory syndrome in children, which became a confounding problem during the COVID-19 pandemic.
-
Challenges in Diagnosing MIS-C
Even though there are clear diagnostic criteria for multisystem inflammatory syndrome in children (MIS-C), the initial diagnosis is not always certain, and there can be overlapping concurrent bacterial, viral, and parasitic infections that also require prompt treatment.
-
Vaccinate Children Against MIS-C, a Serious Post-COVID Syndrome
COVID-19 vaccination can greatly reduce multisystem inflammatory syndrome in children, a rare but serious complication associated with SARS-CoV-2 infection, researchers are finding.
-
Identifying and Managing MIS-C
Pediatric SARS-CoV-2 infections are mild compared to adult infections. However, MIS-C, which typically develops four to six weeks after the initial infection, may be severe and characterized by multiorgan dysfunction resulting from hyperinflammation. This article includes critical information regarding MISC-C recognition and management.
-
COVID-19 Vaccination Prevents Systemic Inflammatory Syndrome (MIS-C)
The estimated effectiveness of two doses of Pfizer-BioNTech vaccine in the prevention of multisystem inflammatory syndrome in children was 91%.
-
MIS-C: Steroids and/or IVIG?
Multisystem inflammatory syndrome in children (MIS-C) can be a devastating post-COVID-19 complication, but treatment seems effective. High-dose steroids and intravenous immune globulin (IVIG) are commonly used, although new studies give conflicting findings as to whether it is best to use both treatments together. -
SARS-CoV-2 Antibodies and Multisystem Inflammatory Syndrome in Children
SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) can be severe and life-threatening. New data suggest that the degree of elevation of spike protein receptor-binding domain antibodies could serve as a diagnostic marker of MIS-C as well as point to potential pathogenic processes.
-
Novel COVID-19 Syndrome in Adults
Healthcare workers could be at risk of multisystem inflammatory syndrome linked to COVID-19, as the poorly understood condition, first seen in children, now is emerging in adults.